Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Awards from Calmes Scholarship Fund help students in ALS families

Having a family member with amyotrophic lateral sclerosis (ALS) can strain household finances as well as the emotions of caregivers and other relatives. To help relieve some of that financial burden, the Jane Calmes ALS Scholarship Fund was established four years ago to support post-high school education for…

ALS survival benefits with Radicava to be studied as part of collaboration

Mitsubishi Tanabe Pharma Canada (MTP-CA) is teaming up with the Canadian Neuromuscular Disease Registry (CNDR) in Canada’s first real-world, evidence-generating study of Radicava (edaravone) in amyotrophic lateral sclerosis (ALS). Data are expected to provide real-life insights into the survival benefits of Radicava in the progressive neurodegenerative…

Merging as EverythingALS, 2 nonprofits seek to better treatment

With an aim to share expertise and diminish duplicative research and care efforts in amyotrophic lateral sclerosis (ALS), two nonprofits — EverythingALS and CureALS — are combining operations on the EverythingALS platform, with an emphasis on research. The new single nonprofit also will tackle efforts to find…

Quebec, Ontario add Albrioza to public reimbursement list

Amylyx Pharmaceuticals Canada has entered into product listing agreements with Quebec and Ontario to publicly reimburse Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), which was recently approved for amyotrophic lateral sclerosis (ALS). The oral therapy, which is marketed in the U.S. as Relyvrio, has been added to the…

MTPA joins with ALS/MND patient registry with goal of better care

To better understand amyotrophic lateral sclerosis (ALS) and improve patient care, Mitsubishi Tanabe Pharma America (MTPA) is partnering with the ALS/MND Natural History Consortium in collecting real-world data on people with the progressive neurodegenerative disorder. The collaboration will give MTPA access to the consortium’s data repository,…

Nonprofit CureALS launches to combat ALS, related disorders

Bill Nuti, the former CEO and chairman of NCR Corporation, is on a mission to eliminate amyotrophic lateral sclerosis (ALS). Nuti, who stepped away from NCR in 2018 after being diagnosed with ALS, has launched CureALS, a nonprofit that will draw on funding, partnerships, data sourcing, and artificial intelligence…

All MLB teams playing on Lou Gehrig Day June 2

Today marks the third annual Major League Baseball (MLB) Lou Gehrig Day, set aside to honor the legacy of the famed New York Yankees first baseman whose career was shortened by amyotrophic lateral sclerosis (ALS). For the first time since the event began, all 30 MLB teams have…